3George R Bailie.Calcium and phosphorus management in chronic kidney disease:Challenges and trends.Health Module,2004,39(7):358-353
4Cunningham J.What is the optimal regimen for vitamin D?Kidney Int,1993,73 (suppl):859-864
5Fernandez E,Borras M,Pais B,et al.Low-calcium dialysate stimulate parathormone secretion and its long-term use worse secondary hyperparathyroidism.J Am Soc Nephrol,1995,6:132-135
6Braun J,Oldendorf M,Moshage W,et al.Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients.Am J Kidney Dis,1996,27:394-401
7Albaaj F,Hutchison A,Hyperphosphataemia in renal failure:Causes,consequences and current management.Drug,2003,63:577-596
8Blick GA,Hulbert-Shearon TE,Levin NW,et al.Association of serum phosphorus and calcium phosphate productwith mortality risk in chronic hemodialysis patients:A national study.Am J Kidney Dis,1998,31:607-617
4Slatopolsky E,Brown A,Dusso A. Pathogenesis of sec- ondary hyperparathyroidism [J]. Am J Kidney Dis, 1994, 23 : 229-236.
5William GG. Calcimimetic agents and secondary hyperpa- rathyroidism:rationale for use and results from clinical tri- als [J]. Pediatr Nephrol,2003,18 : 1206-1212.
6Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone) :alfacalcidol and dox- ercalciferol [J]. Molecules ,2009,14(10) :3869-3880.
7Katrina R. Chronic kidney disease :Doxercalciferol is as effective as calcitriol for the treatment of secondary hy- perparathyroidism in CKD [J]. Nat Rev Nephrology,2010, 6(12) :692-701.
8Holick M ,Smith E,Pincus S. Skin as the site of vitamin D synthesis and target tissue for 1,25 dihydroxyvitamin D3 [J]. Arch Dermatol, 1987,123 : 1676-1683.
9Pierides A. Pharmacology and therapeutic use of vitamin D and its analogues [J]. Drugs, 1981,21:241-256.
10Vitamin D and Analogs (Systemic). http://www.drugs.com/ mmx/calcijex.html?printable= 1.
